source
- 'Incorrect and misleading' data prompted decision to pull Tavneos in EuropeEuropean regulators on Thursday detailed their skepticism of data behind Amgen's rare disease drug Tavneos, explaining a decision last week to pull the drug from the market there. In new documents ...Endpoints · 44m ago↗ source
- PDS halts work on phase 3 cancer therapy to focus on colorectal contenderPDS Biotechnology has called time on its phase 3 head and neck cancer therapy to channel resources to a drug in phase 2 development for metastatic colorectal cancer.Fierce Biotech · 9h ago↗ source
- PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry marketPTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease program for $111 million upfront, outbidding Astellas and TerSera Therapeutics for the near-approval gene therapy. Sang…